Eli Lilly and Company (LLY)

$1,003.57 -4.16 (-0.41%)
Market Cap 950.65B
Revenue (ttm) 65.18B
Net Income (ttm) 20.64B
EPS (ttm) N/A
PE Ratio 42.05
Forward PE 29.33
Profit Margin 31.67%
Debt to Equity Ratio 1.54
Volume 1,965,539
Avg Vol 3,168,792
Day's Range N/A - N/A
Shares Out 943.36M
Stochastic %K 18%
Beta 0.40
Analysts Strong Sell
Price Target $1,238.64

Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncolog...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 317 276 2000
Address:
Lilly Corporate Center, Indianapolis, United States
biolover
biolover Mar. 5 at 2:18 AM
$VKTX CEO today spent a lot on the “ trigger BMI levels “ We know one of them is BMI 24 of no escalation or de escalation if needed. The large space on Truist report for this “ trigger BMI “ discussion reflects management witnessing widespread rather than scattered deep responses .. C/W pts reports on social media. Management is running trial very good and focusing on retaining pts not just on placebo but on active arms ( that could drop due to excessive wt loss ) , also C/W an update from pts in two sites of about 80 of no cases of DC due to AEs after > 4-6 months. We need to see what happens at 15-17.5 mg. But if extrapolating from $LLY trials there was no difference in DC rate between 10mg and 15 m
0 · Reply
WallStJesus
WallStJesus Mar. 5 at 2:17 AM
$LLY has been in digestion mode so far in early 2026 coming off aggressive buying & big move over the 2nd half of last year.. Today, a repeat July bull bets on potential breakout..
0 · Reply
RunnerSignals
RunnerSignals Mar. 5 at 12:33 AM
unusual options alert: $GLXY $LLY $SHOP $SPOT $TTWO see market whales making bold bets – who's ahead and who's hedging? https://stocksrunner.com/news/2026-03-04-unusual-stocks-options-activity
0 · Reply
CP06Trades
CP06Trades Mar. 4 at 11:50 PM
$LLY
0 · Reply
Bazzzigar
Bazzzigar Mar. 4 at 11:03 PM
$LLY moved to NVO
0 · Reply
BioRich
BioRich Mar. 4 at 10:56 PM
$VERU Haven't forgotten about you. Keep preserving that muscle and let's get a damn deal done! Here are some highlights from the upcoming "4th Obesity & Weight Loss Drug Development Summit." (July 14th-16) The summit specifically highlights $VERU in the same bullets as $NVO, $LLY and $RHHBY and calling them "Innovative Biotech" along with Canary and $MTSR For those interested, here's the link to the Summit and downloading the Agenda is free with this link: Summit Link: https://obesity-weight-loss-summit.com/?utm_source=marketo&utm_medium=email&utm_campaign=primary&utm_content=launch/ev-69725/em-01 Event Guide Link: https://obesity-weight-loss-summit.com/full-event-guide/?utm_source=marketo&utm_medium=email&utm_campaign=primary&utm_content=launch/ev-69725/em-01
0 · Reply
Chamcham34
Chamcham34 Mar. 4 at 9:46 PM
$ABBV - Clear interest in the space - Investment in production dedicated to obesity - Per Steve Wagner they are looking for late stage dual agonists - $8.5B debt raise Stars are aligning. - 7 interested parties in the Metsera deal - $NVO likely bidder maybe even $LLY $VKTX partnership or buyout before Q3
0 · Reply
Vpola
Vpola Mar. 4 at 8:42 PM
$LLY finally green 😂😂
0 · Reply
Quantumup
Quantumup Mar. 4 at 8:41 PM
Truist ( $VKTX ) Sees Little Lag Between VK2735's SQ and Oral Commercial Availability. $LLY $NVO GPCR Here's what Truist said: https://x.com/Quantumup1/status/2029295254491545818?s=20
0 · Reply
nostic
nostic Mar. 4 at 8:06 PM
$RHHBY $PFE $LLY check out $CGTX... big things coming together there in AD & DLB. Approaching prime time for a partnership.
1 · Reply
Latest News on LLY
GLP-1 drugs protect against new or worsening addictions, large study shows

Mar 4, 2026, 6:36 PM EST - 4 hours ago

GLP-1 drugs protect against new or worsening addictions, large study shows

AZN NVO

Baron Health Care Fund Q4 2025 Contributors And Detractors

Mar 3, 2026, 10:18 AM EST - 1 day ago

Baron Health Care Fund Q4 2025 Contributors And Detractors

ACLX ARGX DOCS EHC INSM RDNT SYK

Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 2, 2026, 5:57 PM EST - 2 days ago

Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval

Mar 2, 2026, 3:58 PM EST - 2 days ago

Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval

Why Eli Lilly is Winning the Weight Loss War

Feb 27, 2026, 12:30 PM EST - 5 days ago

Why Eli Lilly is Winning the Weight Loss War

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

Feb 27, 2026, 8:11 AM EST - 5 days ago

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

INCY

Eli Lilly reports additional data on weight-loss pill from diabetes trial

Feb 26, 2026, 6:32 AM EST - 6 days ago

Eli Lilly reports additional data on weight-loss pill from diabetes trial

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

Feb 26, 2026, 6:30 AM EST - 6 days ago

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

Columbia Balanced Fund Q4 2025 Contributors And Detractors

Feb 25, 2026, 11:23 AM EST - 7 days ago

Columbia Balanced Fund Q4 2025 Contributors And Detractors

AMAT BLK GOOGL MSFT TMUS GOOG

Novo Nordisk and Eli Lilly shares both fall after Ozempic price-cut plan

Feb 24, 2026, 7:51 AM EST - 8 days ago

Novo Nordisk and Eli Lilly shares both fall after Ozempic price-cut plan

NVO

Novo's stumbles burnish Lilly's widening lead in weight-loss drugs

Feb 24, 2026, 12:09 AM EST - 8 days ago

Novo's stumbles burnish Lilly's widening lead in weight-loss drugs

NVO

Eli Lilly's Zepbound Gets FDA OK for Multi-Dose Pen

Feb 23, 2026, 12:06 PM EST - 9 days ago

Eli Lilly's Zepbound Gets FDA OK for Multi-Dose Pen

Novo Nordisk's Loss Is Eli Lilly's Gain

Feb 23, 2026, 11:42 AM EST - 9 days ago

Novo Nordisk's Loss Is Eli Lilly's Gain

NVO

Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push

Feb 23, 2026, 9:41 AM EST - 9 days ago

Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push

Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen

Feb 23, 2026, 9:00 AM EST - 9 days ago

Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

Feb 23, 2026, 9:00 AM EST - 9 days ago

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

Novo Nordisk Stock Plunges and Eli Lilly Jumps. It's All Down to This Weight-Loss Drug Trial.

Feb 23, 2026, 6:32 AM EST - 9 days ago

Novo Nordisk Stock Plunges and Eli Lilly Jumps. It's All Down to This Weight-Loss Drug Trial.

NVO

These Stocks Are Today's Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and More

Feb 23, 2026, 5:58 AM EST - 9 days ago

These Stocks Are Today's Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and More

NVDA NVO PSKY

Novo Nordisk pitted a new weight-loss drug against Eli Lilly — and lost

Feb 23, 2026, 5:07 AM EST - 9 days ago

Novo Nordisk pitted a new weight-loss drug against Eli Lilly — and lost

NVO

Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial

Feb 23, 2026, 4:41 AM EST - 9 days ago

Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial

NVO

Our Top 10 High Growth Dividend Stocks - February 2026

Feb 21, 2026, 8:15 AM EST - 11 days ago

Our Top 10 High Growth Dividend Stocks - February 2026

APH AU CIB COKE FIX HWM IBKR

Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China

Feb 19, 2026, 2:52 PM EST - 13 days ago

Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China

NVO

Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)

Feb 19, 2026, 12:15 PM EST - 13 days ago

Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)

CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease

Feb 17, 2026, 4:26 PM EST - 15 days ago

CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease

Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company

Feb 17, 2026, 8:00 AM EST - 15 days ago

Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company

Lilly targets India as global export hub amid booming Mounjaro sales, executive says

Feb 17, 2026, 4:49 AM EST - 15 days ago

Lilly targets India as global export hub amid booming Mounjaro sales, executive says

Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors

Feb 16, 2026, 10:58 AM EST - 16 days ago

Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors

AMD GOOG MRK ORCL ZTS

Lilly to participate in TD Cowen's 46th Annual Health Care Conference

Feb 16, 2026, 10:00 AM EST - 16 days ago

Lilly to participate in TD Cowen's 46th Annual Health Care Conference

Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

Feb 16, 2026, 6:45 AM EST - 16 days ago

Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

Is LLY Stock Headed To $1,350?

Feb 13, 2026, 7:26 AM EST - 19 days ago

Is LLY Stock Headed To $1,350?

Prices, pipelines and patent cliffs: Inside pharma's big reset

Feb 13, 2026, 6:13 AM EST - 19 days ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN NVO PFE

Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision

Feb 12, 2026, 3:27 PM EST - 20 days ago

Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision

Baron Opportunity Fund Q4 2025 Contributors And Detractors

Feb 12, 2026, 1:10 AM EST - 20 days ago

Baron Opportunity Fund Q4 2025 Contributors And Detractors

MSFT ORCL SPOT

What Will Drive Eli Lilly Stock's Next Breakout?

Feb 11, 2026, 8:45 AM EST - 21 days ago

What Will Drive Eli Lilly Stock's Next Breakout?

Lilly's bowel disease drug gets approval in China

Feb 11, 2026, 12:26 AM EST - 21 days ago

Lilly's bowel disease drug gets approval in China

Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments

Feb 9, 2026, 9:11 AM EST - 23 days ago

Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion

Feb 9, 2026, 8:37 AM EST - 23 days ago

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion

Eli Lilly Stock Rises. It's Acquiring This Cell Therapy Company for $2.4 Billion.

Feb 9, 2026, 7:18 AM EST - 23 days ago

Eli Lilly Stock Rises. It's Acquiring This Cell Therapy Company for $2.4 Billion.

Lilly to buy Orna Therapeutics for up to $2.4 billion

Feb 9, 2026, 7:06 AM EST - 23 days ago

Lilly to buy Orna Therapeutics for up to $2.4 billion

Lilly to acquire Orna Therapeutics to advance cell therapies

Feb 9, 2026, 7:00 AM EST - 23 days ago

Lilly to acquire Orna Therapeutics to advance cell therapies

Innovent Biologics Strikes Partnership Deal With Eli Lilly

Feb 9, 2026, 12:57 AM EST - 23 days ago

Innovent Biologics Strikes Partnership Deal With Eli Lilly

China's Innovent clinches new Lilly deal for immunology, cancer drug development

Feb 8, 2026, 9:32 PM EST - 24 days ago

China's Innovent clinches new Lilly deal for immunology, cancer drug development

LLY Gains on NVO Losses & Outlook for Weight Loss Drug Trade

Feb 8, 2026, 1:00 PM EST - 24 days ago

LLY Gains on NVO Losses & Outlook for Weight Loss Drug Trade

Weight-loss drugs to compete on biggest stage with Super Bowl ads

Feb 7, 2026, 6:07 AM EST - 25 days ago

Weight-loss drugs to compete on biggest stage with Super Bowl ads

NVO

Eli Lilly: Positives Outweigh The Concerns

Feb 5, 2026, 5:28 PM EST - 27 days ago

Eli Lilly: Positives Outweigh The Concerns

Why a $49 weight-loss pill is rattling Novo Nordisk and Eli Lilly

Feb 5, 2026, 2:29 PM EST - 27 days ago

Why a $49 weight-loss pill is rattling Novo Nordisk and Eli Lilly

NVO

Eli Lilly's 2026 Outlook Push Back Demand Fears: Analyst

Feb 5, 2026, 1:44 PM EST - 27 days ago

Eli Lilly's 2026 Outlook Push Back Demand Fears: Analyst

LLY Becomes "Dominant" GLP-1 Winner, NVO Growth Turns Anemic

Feb 5, 2026, 12:30 PM EST - 27 days ago

LLY Becomes "Dominant" GLP-1 Winner, NVO Growth Turns Anemic

biolover
biolover Mar. 5 at 2:18 AM
$VKTX CEO today spent a lot on the “ trigger BMI levels “ We know one of them is BMI 24 of no escalation or de escalation if needed. The large space on Truist report for this “ trigger BMI “ discussion reflects management witnessing widespread rather than scattered deep responses .. C/W pts reports on social media. Management is running trial very good and focusing on retaining pts not just on placebo but on active arms ( that could drop due to excessive wt loss ) , also C/W an update from pts in two sites of about 80 of no cases of DC due to AEs after > 4-6 months. We need to see what happens at 15-17.5 mg. But if extrapolating from $LLY trials there was no difference in DC rate between 10mg and 15 m
0 · Reply
WallStJesus
WallStJesus Mar. 5 at 2:17 AM
$LLY has been in digestion mode so far in early 2026 coming off aggressive buying & big move over the 2nd half of last year.. Today, a repeat July bull bets on potential breakout..
0 · Reply
RunnerSignals
RunnerSignals Mar. 5 at 12:33 AM
unusual options alert: $GLXY $LLY $SHOP $SPOT $TTWO see market whales making bold bets – who's ahead and who's hedging? https://stocksrunner.com/news/2026-03-04-unusual-stocks-options-activity
0 · Reply
CP06Trades
CP06Trades Mar. 4 at 11:50 PM
$LLY
0 · Reply
Bazzzigar
Bazzzigar Mar. 4 at 11:03 PM
$LLY moved to NVO
0 · Reply
BioRich
BioRich Mar. 4 at 10:56 PM
$VERU Haven't forgotten about you. Keep preserving that muscle and let's get a damn deal done! Here are some highlights from the upcoming "4th Obesity & Weight Loss Drug Development Summit." (July 14th-16) The summit specifically highlights $VERU in the same bullets as $NVO, $LLY and $RHHBY and calling them "Innovative Biotech" along with Canary and $MTSR For those interested, here's the link to the Summit and downloading the Agenda is free with this link: Summit Link: https://obesity-weight-loss-summit.com/?utm_source=marketo&utm_medium=email&utm_campaign=primary&utm_content=launch/ev-69725/em-01 Event Guide Link: https://obesity-weight-loss-summit.com/full-event-guide/?utm_source=marketo&utm_medium=email&utm_campaign=primary&utm_content=launch/ev-69725/em-01
0 · Reply
Chamcham34
Chamcham34 Mar. 4 at 9:46 PM
$ABBV - Clear interest in the space - Investment in production dedicated to obesity - Per Steve Wagner they are looking for late stage dual agonists - $8.5B debt raise Stars are aligning. - 7 interested parties in the Metsera deal - $NVO likely bidder maybe even $LLY $VKTX partnership or buyout before Q3
0 · Reply
Vpola
Vpola Mar. 4 at 8:42 PM
$LLY finally green 😂😂
0 · Reply
Quantumup
Quantumup Mar. 4 at 8:41 PM
Truist ( $VKTX ) Sees Little Lag Between VK2735's SQ and Oral Commercial Availability. $LLY $NVO GPCR Here's what Truist said: https://x.com/Quantumup1/status/2029295254491545818?s=20
0 · Reply
nostic
nostic Mar. 4 at 8:06 PM
$RHHBY $PFE $LLY check out $CGTX... big things coming together there in AD & DLB. Approaching prime time for a partnership.
1 · Reply
TheStockTraderHub
TheStockTraderHub Mar. 4 at 7:49 PM
$LLY LARGE UNUSUAL BULL BET SPOTTED ON @BullflowIO FOR 7/17 EXPIRATION 👀
0 · Reply
DragonAlgo
DragonAlgo Mar. 4 at 7:00 PM
🐉 $LLY CALL — DragonAlgo® Signal Contract: LLY CALL Expiry: 2026-03-06 | Strike: $1000.00 | Type: CALL Option Plan (premium): Entry: $15.15 Stop: $10.91 TP1: $19.70 TP2: $25.75 TP3: $36.36 Rules-based execution profile. 🔗 https://dragonalgo.com
1 · Reply
Vpola
Vpola Mar. 4 at 6:35 PM
$LLY sick of this here, move up 😅
1 · Reply
Flabslab
Flabslab Mar. 4 at 6:10 PM
$LLY Literally the only stock I follow in the red. LOL! NVO up 4.12% HIMS up 4.42% LEXX up 4.46% ALT up 2.04% BKSY up 4.80% Even SOUN is up 0.76% And then there's LLY...down .38%
1 · Reply
Turbofueled
Turbofueled Mar. 4 at 5:42 PM
$LEXX Dont think another BIG PHARMA wont come in and scoop $LEXX up looking at the Results and testing. IMO in doesnt take a rocket scientist to figure out who the PHARMA with the MTA is and anyone that has brains can figure it out with whats been tested.……. Now good results gain other interest and sometimes those that think they hold the cards……… Can lose it very quickly to a competitor if they dont make a swift move!! Big Money with big positioning has been happening!!! PAY ATTENTION!!!! $NVO $LLY $MRK $TEVA
0 · Reply
_AllBullishMoons
_AllBullishMoons Mar. 4 at 5:27 PM
$LLY $NKE $CRM $STX ~
0 · Reply
ChicagoMan
ChicagoMan Mar. 4 at 5:23 PM
$LLY why does the market hate a good business?
2 · Reply
ChiTownGuyinFinance
ChiTownGuyinFinance Mar. 4 at 4:47 PM
$NAGE I just double down - major insider acquisition declared within the last 30 days. $LLY $NVO $PFE - if you’re into anti-aging & longevity, get in on this
2 · Reply
lemon748
lemon748 Mar. 4 at 4:24 PM
$LLY what is support levels here?
1 · Reply
judgeyoung2
judgeyoung2 Mar. 4 at 4:04 PM
$LLY judge chose the one stock that didn’t bounce.
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Mar. 4 at 3:50 PM
$LXRX These likes from Christine are very telling, added to what Exton is saying, there is DEFINITE EYE from $NVO on $LXRX in this battle with $LLY. And guess who's also a lookin... $GILD.... and others I might have missed on that 74 likes and growing list. Anybody else find any other peculiar who's who's reading Extons Posts, let me know. Long.
0 · Reply
Chartguy2000
Chartguy2000 Mar. 4 at 3:41 PM
$LLY Buy the Dips! Eli Lilly's new oral weight-loss drug, orforglipron, is expected to receive FDA approval in early Q2 2026, with a target action date of April 10, 2026. Product availability is expected shortly after approval, as early as Q2 2026 and they can begin shipping the pill within roughly one week of FDA clearance. Broad access in markets outside the United States are projected for 2027. It appears the company has already built a pre-launch inventory worth $1.5 billion to ensure immediate supply and avoid the shortages that affected earlier GLP-1 launches.
1 · Reply